In 2018 alone, 583,405 cases of Neisseria gonorrhoeae and 1,758,688 cases of Chlamydia trachomatis were reported to the Centers for Diseases Control and Prevention, representing an increase of 63% and 19%, respectively, since 2014.1 Approximately 7% to 16% of sexually transmitted infections are diagnosed and treated in emergency departments (EDs), and this trend is likely to continue.2,3 Because of their high sensitivity (>95%) and specificity (>99%), nucleic acid amplification tests (NAATs) are the mainstay of laboratory diagnosis for N gonorrhoeae and C trachomatis and can be performed on first-void urine or specimens obtained from the vagina, endocervix, oropharynx, or rectum.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου